Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conformal Radiation and Chemotherapy for Localized Ependymoma (ACNS0121)
NCT00027846Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Aug 2003
- Primary completion
- Jan 2010
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 6
01
Overview
Phase 2, open-label trial of vincristine sulfate liposome injection, carboplatin, cyclophosphamide and etoposide in ependymoma (3 arms), sponsored by Children's Oncology Group. Primary endpoint: Event-free Survival at 5 years. Started Aug 2003; status: completed.
02
Drugs
vincristine sulfate liposome injectioncarboplatincyclophosphamideetoposide
03
Conditions
ependymoma
Beyond the preview
Go deeper on NCT00027846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027846.